These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 11970990)

  • 1. Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells.
    da Silva AJ; Brickelmaier M; Majeau GR; Li Z; Su L; Hsu YM; Hochman PS
    J Immunol; 2002 May; 168(9):4462-71. PubMed ID: 11970990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD3 zeta dependence of the CD2 pathway of activation in T lymphocytes and natural killer cells.
    Moingeon P; Lucich JL; McConkey DJ; Letourneur F; Malissen B; Kochan J; Chang HC; Rodewald HR; Reinherz EL
    Proc Natl Acad Sci U S A; 1992 Feb; 89(4):1492-6. PubMed ID: 1346934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signal transduction by the CD2 antigen in T cells and natural killer cells: requirement for expression of a functional T cell receptor or binding of antibody Fc to the Fc receptor, Fc gamma RIIIA (CD16).
    Spruyt LL; Glennie MJ; Beyers AD; Williams AF
    J Exp Med; 1991 Dec; 174(6):1407-15. PubMed ID: 1683892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice.
    Majeau GR; Meier W; Jimmo B; Kioussis D; Hochman PS
    J Immunol; 1994 Mar; 152(6):2753-67. PubMed ID: 7511625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Agonistic effects of anti-CD2 and anti-CD16 antibodies on human natural killer killing.
    Uggla CK; Geisberg M; Jondal M; Knowles RW
    Scand J Immunol; 1989 May; 29(5):507-15. PubMed ID: 2567053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alefacept selectively promotes NK cell-mediated deletion of CD45R0+ human T cells.
    Cooper JC; Morgan G; Harding S; Subramanyam M; Majeau GR; Moulder K; Alexander DR
    Eur J Immunol; 2003 Mar; 33(3):666-75. PubMed ID: 12616487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low affinity binding of an LFA-3/IgG1 fusion protein to CD2+ T cells is independent of cell activation.
    Majeau GR; Whitty A; Yim K; Meier W; Hochman PS
    Cell Adhes Commun; 1999; 7(3):267-79. PubMed ID: 10626910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation and expression of the nuclear factors of activated T cells, NFATp and NFATc, in human natural killer cells: regulation upon CD16 ligand binding.
    Aramburu J; Azzoni L; Rao A; Perussia B
    J Exp Med; 1995 Sep; 182(3):801-10. PubMed ID: 7650486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Signaling function of reconstituted CD16: zeta: gamma receptor complex isoforms.
    Vivier E; Rochet N; Ackerly M; Petrini J; Levine H; Daley J; Anderson P
    Int Immunol; 1992 Nov; 4(11):1313-23. PubMed ID: 1472481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T cell receptor-independent CD2 signal transduction in FcR+ cells.
    Arulanandam AR; Koyasu S; Reinherz EL
    J Exp Med; 1991 Apr; 173(4):859-68. PubMed ID: 1706751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of CD16 (Fc receptor III) and interleukin-2 in the reactivation of natural killer cells after inhibitory target cell contact.
    Heiskala M; Ståhls A; Seppälä I; Timonen T
    Nat Immun Cell Growth Regul; 1991; 10(5):265-77. PubMed ID: 1836835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factor VIII moiety of recombinant Factor VIII Fc fusion protein impacts Fc effector function and CD16
    Lagassé HAD; Ou J; Sauna ZE; Golding B
    Front Immunol; 2024; 15():1341013. PubMed ID: 38655263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.
    Ellis CN; Krueger GG;
    N Engl J Med; 2001 Jul; 345(4):248-55. PubMed ID: 11474662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses.
    Miller GT; Hochman PS; Meier W; Tizard R; Bixler SA; Rosa MD; Wallner BP
    J Exp Med; 1993 Jul; 178(1):211-22. PubMed ID: 7686212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of cytolytic activity in CD3- and CD3+ killer cell clones by monoclonal antibodies (anti-CD16, anti-CD2, anti-CD3) depends on subclass specificity of target cell IgG-FcR.
    van de Griend RJ; Bolhuis RL; Stoter G; Roozemond RC
    J Immunol; 1987 May; 138(10):3137-44. PubMed ID: 2952709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Siplizumab Induces NK Cell Fratricide Through Antibody-Dependent Cell-Mediated Cytotoxicity.
    Binder C; Sellberg F; Cvetkovski F; Berg S; Berglund E; Berglund D
    Front Immunol; 2021; 12():599526. PubMed ID: 33643309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of an immunomodulatory LFA3-IgG1 fusion protein on nonhuman primates.
    Chisholm PL; Williams CA; Jones WE; Majeau GR; Oleson FB; Burrus-Fischer B; Meier W; Hochman PS
    Ther Immunol; 1994 Aug; 1(4):205-16. PubMed ID: 7584496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production of granulocyte/macrophage-colony-stimulating factor by human natural killer cells. Modulation by the p75 subunit of the interleukin 2 receptor and by the CD2 receptor.
    Levitt LJ; Nagler A; Lee F; Abrams J; Shatsky M; Thompson D
    J Clin Invest; 1991 Jul; 88(1):67-75. PubMed ID: 1676038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens.
    Weil-Hillman G; Fisch P; Prieve AF; Sosman JA; Hank JA; Sondel PM
    Cancer Res; 1989 Jul; 49(13):3680-8. PubMed ID: 2471587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The functional activity of Fc gamma RII and Fc gamma RIII on subsets of human lymphocytes.
    Hadley AG; Zupanska B; Kumpel BM; Leader KA
    Immunology; 1992 Jul; 76(3):446-51. PubMed ID: 1356095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.